Le Lézard
Classified in: Health, Science and technology, Business
Subject: LIC

Oramed Granted U.S. Combination Therapy Patent for Oral GLP-1 & Insulin for the Treatment of Diabetes


NEW YORK, May 24, 2022 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery platforms, today announced that the United States Patent and Trademark Office has granted the Company a patent titled "Methods and Compositions for Treating Diabetes."  The patent addresses methods and compositions for treating diabetes mellitus through oral pharmaceutical compositions comprising insulin in combination with Glucagon-like Peptide 1 (GLP-1).

 

Oramed Pharmaceuticals Logo

 

About Oramed Pharmaceuticals

Oramed Pharmaceuticals (Nasdaq/TASE: ORMP) is a platform technology pioneer in the field of oral delivery solutions for drugs currently delivered via injection. Established in 2006, with offices in the United States and Israel, Oramed has developed a novel Protein Oral Delivery (PODtm) technology. Oramed is seeking to transform the treatment of diabetes through its proprietary lead candidate, ORMD-0801, which is being evaluated in two pivotal Phase 3 studies and has the potential to be the first commercial oral insulin capsule for the treatment of diabetes. In addition, Oramed is developing an oral GLP-1 (Glucagon-like peptide-1) analog capsule (ORMD-0901).

For more information, please visit www.oramed.com.

Forward-looking statements:  This press release contains forward-looking statements. For example, we are using forward-looking statements when we discuss the potential of ORMD-0801 to be the first commercial oral insulin capsule for the treatment of diabetes. In addition, historic results of scientific research and clinical trials do not guarantee that the conclusions of future research or trials will suggest identical or even similar conclusions. These forward-looking statements are based on the current expectations of the management of Oramed only, and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements, including the risks and uncertainties related to the progress, timing, cost, and results of clinical trials and product development programs; difficulties or delays in obtaining regulatory approval or patent protection for our product candidates; competition from other pharmaceutical or biotechnology companies; and our ability to obtain additional funding required to conduct our research, development and commercialization activities. In addition, the following factors, among others, could cause actual results to differ materially from those described in the forward-looking statements: changes in technology and market requirements; delays or obstacles in launching our clinical trials; changes in legislation; inability to timely develop and introduce new technologies, products and applications; lack of validation of our technology as we progress further and lack of acceptance of our methods by the scientific community; inability to retain or attract key employees whose knowledge is essential to the development of our products; unforeseen scientific difficulties that may develop with our process; greater cost of final product than anticipated; loss of market share and pressure on pricing resulting from competition; laboratory results that do not translate to equally good results in real settings; our patents may not be sufficient; and finally that products may harm recipients, all of which could cause the actual results or performance of Oramed to differ materially from those contemplated in such forward-looking statements. Except as otherwise required by law, Oramed undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. For a more detailed description of the risks and uncertainties affecting Oramed, reference is made to Oramed' s reports filed from time to time with the Securities and Exchange Commission.

Company Contacts:
Zach Herschfus
+1-844-9-ORAMED
[email protected]

Logo - https://mma.prnewswire.com/media/1724339/Oramed_Logo.jpg

SOURCE Oramed Pharmaceuticals Inc.


These press releases may also interest you

at 16:13
The Prime Minister, Justin Trudeau, today concluded his participation in the 2022 Commonwealth Heads of Government Meeting (CHOGM) in Kigali, Rwanda, where he worked closely with international partners to address key priorities, like food security,...

at 15:22
The founders of Country Roads RV Center are pleased to announce their current sales, promotions and updates for June, 2022.  To learn more about Country Roads and check out their latest news, please...

at 11:08
Corsicana Mattress Company and certain of its affiliated entities filed for voluntary reorganization today under Chapter 11 of the U.S. Bankruptcy Code in the Northern District of Texas in Fort Worth. The filing indicated that Corsicana will be...

at 09:52
Canadians deserve high-quality and efficient government services that are accessible, timely, and make their lives easier. The delays in immigration application and passport processing are unacceptable and the Government of Canada is urgently working...

at 07:00
Note: All times local Kigali, Rwanda Private meetings 8:00 a.m. The Prime Minister will participate in an intergenerational dialogue breakfast with Commonwealth youth leaders. Kigali Convention Centre Note for media: Pooled coverage9:00 a.m. The...

at 06:15
Using Verv, business customers in Europe can open a digital bank account with its unique IBAN ? International Bank Account Number ? for standardised banking services worldwide. This is the international equivalent of Australia's BSB system but on a...



News published on 24 may 2022 at 08:10 and distributed by: